APstem News
Publications
Human stem cells with in vivo high plasticity generated by cell–cell communication
Proceedings of the National Academy of Sciences of the United States of America
Treatment of Full-Thickness Skin Wounds with Blood-Derived CD34+ Precursor Cells Enhances Healing with Hair Follicle Regeneration
Advances in Wound Care
Expansion and Hepatic Differentiation of Adult Blood-Derived CD34+ Progenitor Cells and Promotion of Liver Regeneration After Acute Injury
Stem Cell Translational Medicine
Peripheral Blood‐Derived Mesenchymal Stem Cells: Candidate Cells Responsible for Healing Critical‐Sized Calvarial Bone Defects
Stem Cell Translational Medicine
News & Media
In 2024, APstem presented poster entitled “REVERSING TYPE I DIABETES IN NOD MICE BY HUMAN HIGH-PLASTICITY STEM CELLS” in ISSCR Copenhagen International Symposium, “PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success.”
In 2023, APstem had a pre-IND meeting with the FDA regarding AP-Skin-01, an “off-the-shelf” allogeneic stem cell product for the treatment of diabetic ulcers.
In 2019, APstem presented poster entitled “TREATMENT OF DIABETIC ULCERS WITH ACTIVATED ADULT STEM/PRECURSOR CELLS” in ISSCR Toronto International Symposium, “From Stem Cell Biology to New Therapies.”
APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an “Off-the-Shelf” Allogeneic Stem Cell Product for the Treatment of Diabetic Ulcers
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
The Funded: StartX Extends COVID-19 Demo Day
Inside the Silicon Valley ‘brain trust’ taking aim at COVID-19